DepYmed


DepYmed Inc. is a New York-based cancer and rare disease therapeutic development company. DepYmed is currently developing potent inhibitors of the enzyme PTP1B (protein tyrosine phosphatase 1B) as potential novel therapeutics for HER2-positive breast cancer and Rett Syndrome.

Industries

Employees

1-10

Links


Org chart

Andreas G. Grill
President & CEO
Collapse
Peter Van Ess
Senior Vice President Of Early Development

Board & advisors

Peter Young
Director & Corporate Secretary
Steve Winick
Director
Leo Guthart
Director
Nicholas Tonks
Scientific Advisor


Offices